The reduction in price target from $12 to $7 by a reputable analyst firm like HC Wainwright & Co. could lead to a negative short-term sentiment among investors, potentially causing a decrease in the stock price of Enlivex Therapeutics. The maintenance of a Buy rating indicates a positive outlook on the company's fundamentals, but the significant cut in the price target may overshadow this and result in short-term price pressure.